Selwyn Ho
Chief Executive Officer at MEDIGENE AG
Net worth: 66 085 $ as of 2024-03-30
Profile
Selwyn Ho is the founder of Artemis Catalyst Ltd.
which was founded in 2017.
He is currently the Chief Executive Officer at MediGene AG and a Non-Executive Director at Immodulon Therapeutics Ltd.
He previously worked as the UK Managing Director & Country Manager at Allergan Ltd., Vice President & Global Missions Lead-Cimzia at UCB SA from 2013 to 2015, VP, Head-Market Access & Strategic Marketing at Dermira, Inc. from 2016 to 2017, and Chief Business Officer at Connect Biopharma Holdings Ltd.
Dr. Ho received his undergraduate degree from Imperial College London.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
MEDIGENE AG
0.12% | 2023-06-29 | 29,000 ( 0.12% ) | 66 085 $ | 2024-03-30 |
Selwyn Ho active positions
Companies | Position | Start |
---|---|---|
MEDIGENE AG | Chief Executive Officer | 2022-07-24 |
Artemis Catalyst Ltd. | Founder | 2017-09-30 |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The private company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Director/Board Member | 2022-06-13 |
Former positions of Selwyn Ho
Companies | Position | End |
---|---|---|
DERMIRA, INC. | Corporate Officer/Principal | 2017-08-31 |
UCB | Corporate Officer/Principal | - |
Allergan Ltd.
Allergan Ltd. Pharmaceuticals: MajorHealth Technology Allergan Ltd. provides eye care and specialty pharmaceutical products. It develops pharmaceutical products used for treatment of eye and skin care medications and neurological disorders. The firm develops products for glaucoma, dry eye, blepharospasm, cervical, dystonia, hemi-facial spasm, post-stroke spasticity and cerebral palsy. The company was founded in 1977 and is headquartered in Marlow, the United Kingdom. | Corporate Officer/Principal | - |
CONNECT BIOPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | - |
Training of Selwyn Ho
Imperial College London | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
UCB | Health Technology |
MEDIGENE AG | Health Technology |
CONNECT BIOPHARMA HOLDINGS LIMITED | Health Technology |
Private companies | 4 |
---|---|
Allergan Ltd.
Allergan Ltd. Pharmaceuticals: MajorHealth Technology Allergan Ltd. provides eye care and specialty pharmaceutical products. It develops pharmaceutical products used for treatment of eye and skin care medications and neurological disorders. The firm develops products for glaucoma, dry eye, blepharospasm, cervical, dystonia, hemi-facial spasm, post-stroke spasticity and cerebral palsy. The company was founded in 1977 and is headquartered in Marlow, the United Kingdom. | Health Technology |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The private company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Health Technology |
Dermira, Inc.
Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
Artemis Catalyst Ltd. |
- Stock Market
- Insiders
- Selwyn Ho